1. S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial. (27th September 2022) Authors: Humrich, J; Cacoub, P; Rosenzwajg, M; Pitoiset, F; Pham, H; Guidoux, J; Leroux, D; Vazquez, T; Riemekasten, G; Smolen, J; Tsokos, G; Klatzmann, D Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 2 Page Start: A16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗